Syntach Receives €17.5M in Equity Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
Occlutech Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Occlutech Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Occlutech Group Today - Breaking & Trending Today
Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q
/PRNewswire/ - Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the...
Source: prnewswire.com
Occlutech takes important step towards approval in
Occlutech AG ("Occlutech" or the "Company") today announces that the planned recruitment of 180
Source: ryt9.com
New members elected to Occlutech Board of
Medical device company Occlutech Holding AG, one of the world?s leading providers of minimally invasive structural heart disease devices, announces the election of four new members to the board Occlutech Holding AG ( "Occlutech") today announces that Marianne Dicander Alexandersson, Mette-Marie Harild, Helena Levander, and Michel Lussier have been elected as members of the Board of Directors of Occlutech. Marianne Dicander Alexandersson will be nominated as the Chair of the Board of Directors of Occlutech at the Annual General Meeting on 18 June 2021. "We are delighted to welcome Marianne, Me...
Source: ryt9.com
Occlutech's Atrial Flow Regulator for Heart Failure Receives FDA Breakthrough Device Designation
Occlutech's Atrial Flow Regulator for Heart Failure Receives FDA Breakthrough Device Designation The Occlutech implantable Atrial Flow Regulator (AFR) maintains an interatrial shunt with a predetermined diameter allowing for controlled blood flow from the left to the right atrium enabling the left atrium to decompress and lower left atrial pressure. This reduced left atrial pressure reduces heart failure symptoms and improves exercise tolerance. January, 27, 2021 — The U.S. Food and Drug Administration (FDA) has granted Occlutech a Breakthrough Device designation for its first-in-class,...
Source: dicardiology.com